Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy
Introduction: The introduction of immune checkpoint inhibitors (ICIs) has opened a new chapter in cancer treatment. Nevertheless, their use may result in immune-related adverse events (irAEs) with multifactorial determinants, complex mechanisms, and varying clinical implications. In specific cancer...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2024-03-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/536288 |
| _version_ | 1827293844914307072 |
|---|---|
| author | Melina Yerolatsite Nanteznta Torounidou Anna-Lea Amylidi Fani Kapoulitsa Eleftherios Kampletsas George Zarkavelis Davide Mauri |
| author_facet | Melina Yerolatsite Nanteznta Torounidou Anna-Lea Amylidi Fani Kapoulitsa Eleftherios Kampletsas George Zarkavelis Davide Mauri |
| author_sort | Melina Yerolatsite |
| collection | DOAJ |
| description | Introduction: The introduction of immune checkpoint inhibitors (ICIs) has opened a new chapter in cancer treatment. Nevertheless, their use may result in immune-related adverse events (irAEs) with multifactorial determinants, complex mechanisms, and varying clinical implications. In specific cancer types, like melanoma, irAEs exhibit a complex relationship with patient outcomes. Case Presentation: We present a case of febrile neutropenia following ICI therapy in a patient with metastatic melanoma, underscoring the intricate clinical landscape associated with irAEs in the context of cancer immunotherapy. More specifically, a 68-year-old man was diagnosed with metastatic malignant melanoma and administered a combination of nivolumab and ipilimumab. However, after a single dose, the patient was hospitalized due to febrile neutropenia. The patient eventually recovered, but a diagnosis of myelosuppression related to prior immunotherapy led to treatment discontinuation. Subsequently, the patient transitioned to a second-line therapy. Conclusion: This case contributes to our comprehension of rare yet potentially severe hematological irAEs and their influence on immunotherapy outcomes. Such insights will guide future diagnostic and therapeutic strategies in the field of immunotherapy. |
| first_indexed | 2024-04-24T13:45:53Z |
| format | Article |
| id | doaj.art-2d965df517914da59828fbf9df33838d |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-24T13:45:53Z |
| publishDate | 2024-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-2d965df517914da59828fbf9df33838d2024-04-04T06:12:58ZengKarger PublishersCase Reports in Oncology1662-65752024-03-0117141742210.1159/000536288536288Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving ImmunotherapyMelina Yerolatsite0Nanteznta Torounidou1Anna-Lea Amylidi2Fani Kapoulitsa3Eleftherios Kampletsas4George Zarkavelis5Davide Mauri6Department of Medical Oncology, University Hospital of Ioannina, Ioannina, GreeceDepartment of Medical Oncology, University Hospital of Ioannina, Ioannina, GreeceDepartment of Medical Oncology, University Hospital of Ioannina, Ioannina, GreeceDepartment of Medical Oncology, University Hospital of Ioannina, Ioannina, GreeceDepartment of Medical Oncology, University Hospital of Ioannina, Ioannina, GreeceDepartment of Medical Oncology, University Hospital of Ioannina, Ioannina, GreeceDepartment of Medical Oncology, University Hospital of Ioannina, Ioannina, GreeceIntroduction: The introduction of immune checkpoint inhibitors (ICIs) has opened a new chapter in cancer treatment. Nevertheless, their use may result in immune-related adverse events (irAEs) with multifactorial determinants, complex mechanisms, and varying clinical implications. In specific cancer types, like melanoma, irAEs exhibit a complex relationship with patient outcomes. Case Presentation: We present a case of febrile neutropenia following ICI therapy in a patient with metastatic melanoma, underscoring the intricate clinical landscape associated with irAEs in the context of cancer immunotherapy. More specifically, a 68-year-old man was diagnosed with metastatic malignant melanoma and administered a combination of nivolumab and ipilimumab. However, after a single dose, the patient was hospitalized due to febrile neutropenia. The patient eventually recovered, but a diagnosis of myelosuppression related to prior immunotherapy led to treatment discontinuation. Subsequently, the patient transitioned to a second-line therapy. Conclusion: This case contributes to our comprehension of rare yet potentially severe hematological irAEs and their influence on immunotherapy outcomes. Such insights will guide future diagnostic and therapeutic strategies in the field of immunotherapy.https://beta.karger.com/Article/FullText/536288immune checkpoint inhibitorsimmune-related adverse eventsneutropeniamelanomacase reportctla-4pd-1 |
| spellingShingle | Melina Yerolatsite Nanteznta Torounidou Anna-Lea Amylidi Fani Kapoulitsa Eleftherios Kampletsas George Zarkavelis Davide Mauri Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy Case Reports in Oncology immune checkpoint inhibitors immune-related adverse events neutropenia melanoma case report ctla-4 pd-1 |
| title | Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy |
| title_full | Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy |
| title_fullStr | Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy |
| title_full_unstemmed | Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy |
| title_short | Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy |
| title_sort | exploring immune related adverse events a case of febrile neutropenia in a melanoma patient receiving immunotherapy |
| topic | immune checkpoint inhibitors immune-related adverse events neutropenia melanoma case report ctla-4 pd-1 |
| url | https://beta.karger.com/Article/FullText/536288 |
| work_keys_str_mv | AT melinayerolatsite exploringimmunerelatedadverseeventsacaseoffebrileneutropeniainamelanomapatientreceivingimmunotherapy AT nantezntatorounidou exploringimmunerelatedadverseeventsacaseoffebrileneutropeniainamelanomapatientreceivingimmunotherapy AT annaleaamylidi exploringimmunerelatedadverseeventsacaseoffebrileneutropeniainamelanomapatientreceivingimmunotherapy AT fanikapoulitsa exploringimmunerelatedadverseeventsacaseoffebrileneutropeniainamelanomapatientreceivingimmunotherapy AT eleftherioskampletsas exploringimmunerelatedadverseeventsacaseoffebrileneutropeniainamelanomapatientreceivingimmunotherapy AT georgezarkavelis exploringimmunerelatedadverseeventsacaseoffebrileneutropeniainamelanomapatientreceivingimmunotherapy AT davidemauri exploringimmunerelatedadverseeventsacaseoffebrileneutropeniainamelanomapatientreceivingimmunotherapy |